Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

Mepolizumab, an interleukin-5 antagonist, is globally recognized for its efficacy in randomized controlled trials for the treatment of severe eosinophilic asthma. The present study explored its real-world effectiveness and safety in a Korean cohort, filling a critical gap in current research. This m...

Full description

Saved in:

Bibliographic Details
Published in:	Allergy, asthma & immunology research 2025, Asthma & Immunology Research, 17(3), , pp.384-393
Main Authors:	Park, So-Young, Lee, Daegeun, Kim, Joo-Hee, Lee, Youngsoo, Ban, Ga-Young, Sim, Da Woon, Kwon, Jae-Woo, Kim, So Ri, Song, Woo-Jung, Park, Heung-Woo, Chang, Yoon-Seok, Koh, Young-Il, Lee, Byung-Jae, Park, Hae-Sim, Cho, You Sook, Kim, Sang-Heon
Format:	Article
Language:	English
Subjects:	Asthma Brief Communication Clinical trials Effectiveness Interleukin 5 Leukocytes (eosinophilic) Lungs Maintenance Quality of life Respiratory function Safety 내과학
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!